Shanghai Heartcare Medical Technology Corp. Ltd. Class H (HK:6609) has released an update.
Shanghai HeartCare Medical Technology Corporation Limited reports a 17.2% year-on-year increase in revenue for the first half of 2024, with a remarkable reduction in loss before tax by 94.1%. The company attributes its financial improvements to expanding business scale, cost control, and efficiency enhancement measures. Additionally, it’s focusing on the development and future launch of advanced neuro-interventional treatment devices, aiming to strengthen its market position in the growing Chinese healthcare sector and expand its international footprint with various products achieving CE or FDA certification.
For further insights into HK:6609 stock, check out TipRanks’ Stock Analysis page.
